Up next

Autoplay

MARS: mutation-adjusted risk score for advanced systemic mastocytosis

1 Views • 07/09/23
Share
Embed
administrator
administrator
Subscribers
0

Andreas Reiter, MD, University Medical Centre, Mannheim, Germany, discusses how a mutation-adjusted risk score (MARS) may improve treatment stratification for advanced systemic mastocytosis (AdvSM). This interview took place at the Myeloproliferative Neoplasms Advances Day 2019 in London, UK.

Show more
0 Comments sort Sort By
Facebook Comments

Up next

Autoplay